文献速递临床试验与 GCP流行病学与生物统计

高剂量与标准剂量冬季维生素D补充对 young healthy children 病毒性上呼吸道感染的影响

Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children.
PubMed 文献 · JAMA · 2017-01-01

该随机临床试验在加拿大安大略省多伦多市的多站点初级保健研究网络TARGet Kids!中,纳入1至5岁健康儿童,比较冬季每日补充2000 IU与400 IU维生素D对实验室确诊病毒性上呼吸道感染的影响。结果显示,高剂量组与标准剂量组在实验室确诊感染数、首次感染时间及家长报告的上呼吸道疾病数方面均无统计学显著差异。作者认为这些发现不支持常规使用高剂量维生素D补充来预防儿童病毒性上呼吸道感染。

要点

  • 高剂量组与标准剂量组实验室确诊上呼吸道感染数无统计学显著差异(发病率比RR 0.97;95%CI 0.80-1.16)。
  • 高剂量组与标准剂量组首次实验室确诊感染的中位时间无显著差异。
  • 研究结束时高剂量组血清25-羟基维生素D水平为48.7 ng/mL,标准剂量组为36.8 ng/mL。

核心结论

  • 在1至5岁健康儿童中,每日补充2000 IU相比400 IU维生素D并未减少冬季总体上呼吸道感染。
  • 这些发现不支持常规使用高剂量维生素D补充来预防儿童病毒性上呼吸道感染。

研究设计与样本

  • 随机临床试验于2011年9月13日至2015年6月30日冬季月份开展,纳入加拿大安大略省多伦多市TARGet Kids!多站点初级保健研究网络中1至5岁儿童。
  • 349名参与者随机接受每日2000 IU维生素D口服补充(高剂量组),354名参与者随机接受每日400 IU(标准剂量组),补充至少4个月(9月至5月期间)。
  • 共703名参与者随机分组(平均年龄2.7岁,57.7%为男孩),699名(99.4%)完成试验。

主要发现

  • 高剂量组每名儿童实验室确诊上呼吸道感染平均数为1.05(95%CI 0.91-1.19),标准剂量组为1.03(95%CI 0.90-1.16),组间差异为每名儿童0.02(95%CI -0.17至0.21)。
  • 两组实验室确诊感染数无统计学显著差异(发病率比RR 0.97;95%CI 0.80-1.16)。
  • 首次实验室确诊感染的中位时间:高剂量组3.95个月(95%CI 3.02-5.95个月) vs 标准剂量组3.29个月(95%CI 2.66-4.14个月),无显著差异。
  • 家长报告的上呼吸道疾病数:高剂量组625 vs 标准剂量组600,发病率比RR 1.01(95%CI 0.88-1.16),组间无显著差异。
  • 研究结束时血清25-羟基维生素D水平:高剂量组48.7 ng/mL(95%CI 46.9-50.5 ng/mL) vs 标准剂量组36.8 ng/mL(95%CI 35.4-38.2 ng/mL)。

关键数值与推荐

  • 主要结局为冬季月份基于家长采集鼻拭子的实验室确诊病毒性上呼吸道感染数。
  • 次要结局包括流感感染数、非流感感染数、家长报告的上呼吸道疾病数、首次上呼吸道感染时间及研究终止时血清25-羟基维生素D水平。

临床怎么用

  • 作者认为这些发现不支持常规使用高剂量维生素D补充来预防儿童病毒性上呼吸道感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epidemiological studies support a link between low 25-hydroxyvitamin D levels and a higher risk of viral upper respiratory tract infections. However, whether winter supplementation of vitamin D reduces the risk among children is unknown. OBJECTIVE: To determine whether high-dose vs standard-dose vitamin D supplementation reduces the incidence of wintertime upper respiratory tract infections in young children. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted during the winter months between September 13, 2011, and June 30, 2015, among children aged 1 through 5 years enrolled in TARGet Kids!, a multisite primary care practice-based research network in Toronto, Ontario, Canada. INTERVENTIONS: Three hundred forty-nine participants were randomized to receive 2000 IU/d of vitamin D oral supplementation (high-dose group) vs 354 participants who were randomized to receive 400 IU/d (standard-dose group) for a minimum of 4 months between September and May. MAIN OUTCOME MEASURES: The primary outcome was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected nasal swabs over the winter months. Secondary outcomes included the number of influenza infections, noninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin D levels at study termination. RESULTS: Among 703 participants who were randomized (mean age, 2.7 years, 57.7% boys), 699 (99.4%) completed the trial. The mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (95% CI, 0.91-1.19) for the high-dose group and 1.03 (95% CI, 0.90-1.16) for the standard-dose group, for a between-group difference of 0.02 (95% CI, -0.17 to 0.21) per child. There was no statistically significant difference in number of laboratory-confirmed infections between groups (incidence rate ratio [RR], 0.97; 95% CI, 0.80-1.16). There was also no significant difference in the median time to the first laboratory-confirmed infection: 3.95 months (95% CI, 3.02-5.95 months) for the high-dose group vs 3.29 months (95% CI, 2.66-4.14 months) for the standard-dose group, or number of parent-reported upper respiratory tract illnesses between groups (625 for high-dose vs 600 for standard-dose groups, incidence RR, 1.01; 95% CI, 0.88-1.16). At study termination, serum 25-hydroxyvitamin D levels were 48.7 ng/mL (95% CI, 46.9-50.5 ng/mL) in the high-dose group and 36.8 ng/mL (95% CI, 35.4-38.2 ng/mL) in the standard-dose group. CONCLUSIONS AND RELEVANCE: Among healthy children aged 1 to 5 years, daily administration of 2000 IU compared with 400 IU of vitamin D supplementation did not reduce overall wintertime upper respiratory tract infections. These findings do not support the routine use of high-dose vitamin D supplementation in children for the prevention of viral upper respiratory tract infections. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01419262.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Aglipay M, Birken CS, Parkin PC, et al. Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA. 2017. PMID: 28719693. doi:10.1001/jama.2017.8708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。